Results 191 to 200 of about 72,887 (326)

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group. [PDF]

J Gynecol Oncol, 2023
Shimada M, Yoshihara K, Tanigawa T, Nomura H, Hamanishi J, Fujiwara S, Tanabe H, Kajiyama H, Mandai M, Aoki D, Enomoto T, Okamoto A.   +11 more
europepmc   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.
What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source

Cytotoxicity of anticancer drugs and PJ-34 (poly(ADP-ribose)polymerase-1 (PARP-1) inhibitor) on HL-60 and Jurkat cells [PDF]

, 2017
M. Stępnik, Sylwia Spryszyńska, Anna Gorzkiewicz, Magdalena Ferlińska   +3 more
openalex   +1 more source

Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. [PDF]

J Ovarian Res, 2023
Ma Y, Liu J, Li N, Bu H, Huang Y, Jin C, Wen H, Feng S, Zhang H, Yang X, Kong B, Wu L, Song K.   +12 more
europepmc   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

, 2023
Patricia LoRusso, Jing Li, Angelika M. Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney, James M. Cleary, Alice P. Chen, Larry Rubinstein, Julie L. Boerner, Adam Bowditch, Dongpo Cai, Tracy Bell, Andrew Wolanski, Allison M. Marrero, Yiping Zhang, Jiuping Ji, Katherine V. Ferry‐Galow, Robert J. Kinders, Ralph E. Parchment, Geoffrey I. Shapiro   +24 more
openalex   +1 more source

Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder. [PDF]

Investig Clin Urol, 2022
Lee HW, Seo HK.
europepmc   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 618-628, March 2026.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A. Yap, Ruth Plummer, Anthony W. Tolcher, Johann S. de Bono, Ioannis Gounaris, Zoltan Szucs, Astrid Zimmermann, Irina Kareva, Jayaprakasam Bolleddula, Annick Seithel‐Keuth, Giuseppe Locatelli, Marta Enderlin, Christine Hicking, Anup Zutshi, Wei Gao, Rainer Strotmann, Lisa Benincosa, Karthik Venkatakrishnan   +20 more
wiley   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA2 Alterations and Near‐Threshold Tumor Mutational Burden

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Kotaro Yokota, Takeo Kosaka, Tatsuaki Daimon, Shinnosuke Fujiwara, Kohei Nakamura, Hiroshi Nishihara, Mototsugu Oya   +6 more
wiley   +1 more source